Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Recludix launches with $60 million for SH2 inhibitors

by Ryan Cross
November 21, 2021 | A version of this story appeared in Volume 99, Issue 42

 

Recludix Pharma has launched with $60 million in series A funding to use DNA-encoded libraries to discover small-molecule drugs. The start-up’s focus is on inhibiting SH2 domains, protein structures important for cell signaling. SH2 domains are linked to several diseases but have proved difficult to drug. Recludix’s lead programs target SH2 domains in the transcription factors STAT3 and STAT6. It plans to test the drugs on cancers and inflammatory diseases.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.